Hexa Reports Regenerative Medicine Marke Size | Page 2

Identification of ability of stem cells to develop into various different cell lines further propelled the
advancements in regenerative medicine. Frequent media exposure due to regulatory as well as ethical
controversies around embryonic stem cells has increased awareness among the masses. This encouraged
researchers to explore and develop other potential fields for similar applications, such as induced pluripotent
stem cells (iPSC).
Furthermore, the emergence of gene therapy techniques with potential to rectify and restore effects of gene
mutations in cells is under development. Conditions caused due to Single Nucleotide Polymorphism (SNP) as
well as mutations that induce degenerative characteristics are primarily targeted.
Biologics, individually or in combination with cells or devices, are explored to support regenerate the biological
functions of cells, tissues, or organs. A number of combinatorial therapies to support chemotherapy and other
cancer treatments by prevention as well as treatment for cancer relapse are in development phases.
In addition, rising prevalence of complicated degenerative disorders such as age-related macular
degeneration, Alzheimer's disease, and Parkinson's disease, especially in the aging population resulted in high
investments in R&D to develop therapeutic solutions.
Regenerative medicine grabs the attention of the healthcare industry owing to its promising applications along
with significant advances in supportive fields including tissue engineering, stem cells, gene therapy, drug
discovery and nanotechnology. For instance, 3D printing over scaffold with stem cells to restore structure as
well as functional characteristics of biological cells, tissues, and organs.
Request A Sample copy of This Report @
https://www.hexareports.com/report/regenerative-medicine-market/request-sample
Further key findings from the report suggest:
•
•
•
•
•
The global regenerative medicine demand exceeded USD 1.7 billion in 2016 and is expected to grow at
a considerable rate over the forecast period owing to the presence of a strong looking product pipeline
with anticipated commercializations just around the corner
Therapeutics emerged as the largest product segment in 2016 as it has a relatively high
implementation and usage rate resulting in higher adoption
Global regenerative services demand for facilities such as tissue banks and cellular engineering tools is
expected to drive demand in the segment
The industry in Asia Pacific is projected to witness substantial growth over the next decade owing to
various developments across major economies with increased focus of dominant players in emerging
economies is attributive to market growth. market.
Key players including Asterias Bio, Athersys, Integra LifeSciences Corpotation, and MiMedx are involved
in complex technical cum financial partnerships with larger players in an attempt to expedite R&D
Follow Us: